Michael Stepanavage

Statistics

Publications

Citations

1.8K

H-Index

Active since

1997

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Thrombolysis in Myocardial Infarction Study Group

University of Utah

Radiant Research (United States)

The Heart Research Institute

Michael Stepanavage is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, pharmacotherapy, and clinical pharmacology.

Publications per year

1997–2012

Publications

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Christopher P. Cannon, Sukrut Shah, Hayes M. Dansky et al. · New England Journal of Medicine · 2010 · 754 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia

Saskia de Jongh, Leiv Ose, Tamás Szamosi et al. · Circulation · 2002 · 311 citations

Pharmacy, Pediatrics, Pharmacotherapy +17

Some statistical methods for multiple endpoints in clinical trials

Ji Zhang, Hui Quan, Jennifer Ng et al. · Controlled Clinical Trials · 1997 · 171 citations

Public Health, Biostatistics, Experimental Design +14

Pregnancy outcomes after maternal exposure to simvastatin and lovastatin

Pia S. Pollack, Kristine E. Shields, Diane M. Burnett et al. · Birth Defects Research Part A Clinical and Molecular Teratology · 2005 · 107 citations

Medicine, Obstetrics, Pharmacotherapy +17

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

Christopher P. Cannon, Hayes M. Dansky, Michael H. Davidson et al. · American Heart Journal · 2009 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +3

1–5 of 11